Search

Displaying results 251 - 260 of 536 in total
  1. Drug

    Tabirafusp tedromer

    go.drugbank.com/drugs/DB19340
    Investigational

    Tabirafusp tedromer is under investigation in clinical trial NCT06556368 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants

    Synonyms: 3,5,8-Trioxa-4-phosphaundec-10-en-1-aminium,4-hydroxy-N,N,N,10-tetramethyl-9-oxo-, inner salt, 4-oxide, homopolymer,9-arm star compd. with 1,1'-[2-[11,11-bis[15-bromo-11,11-bis[(2-bromo-2-methyl-1-oxopropoxy
  2. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.

  3. Drug

    Promethazine

    go.drugbank.com/drugs/DB01069
    ApprovedInvestigational

    [A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]

  4. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali.

  5. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare

  6. Target

    Vitamin K epoxide reductase complex subunit 1-like protein 1

    go.drugbank.com/bio_entities/BE0002329
    TargetHumans

    Involved in vitamin K metabolism. Can reduce inactive vitamin K 2,3-epoxide to active vitamin K, and may contribute to vitamin K-mediated protection against oxidative stress. Plays a role in vitamin K-dependent gamma-carboxylation of Glu...

    Polypeptides: Vitamin K epoxide reductase complex subunit 1-like protein 1
  7. Target

    Insulin-like growth factor-binding protein complex acid labile subunit

    go.drugbank.com/bio_entities/BE0009058
    TargetCarrierHumans

    Involved in protein-protein interactions that result in protein complexes, receptor-ligand binding or cell adhesion

    Polypeptides: Insulin-like growth factor-binding protein complex acid labile subunit
  8. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]

  9. Drug

    Ociperlimab

    go.drugbank.com/drugs/DB18947
    Investigational

    Ociperlimab is under investigation in clinical trial NCT04866017 (A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (Ccrt) in Patients With Stage

  10. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Normiflo was withdrawn from the US market in March 2000.